DarioHealth Corp. (DRIO) Research Coverage Started at Aegis
Aegis began coverage on shares of DarioHealth Corp. (NASDAQ:DRIO) in a research report report published on Tuesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $3.50 price target on the stock.
Shares of DarioHealth Corp. (DRIO) opened at 1.96 on Tuesday. The firm’s market capitalization is $19.12 million. DarioHealth Corp. has a 52 week low of $1.81 and a 52 week high of $4.70. The stock’s 50 day moving average price is $2.36 and its 200 day moving average price is $2.85.
DarioHealth Corp. (NASDAQ:DRIO) last released its earnings results on Monday, August 14th. The company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.13. The firm had revenue of $1.21 million for the quarter. DarioHealth Corp. had a negative return on equity of 626.32% and a negative net margin of 206.95%. On average, analysts predict that DarioHealth Corp. will post ($0.62) EPS for the current fiscal year.
About DarioHealth Corp.
DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter.
Receive News & Stock Ratings for DarioHealth Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth Corp. and related stocks with our FREE daily email newsletter.